Page last updated: 2024-11-05

trihexyphenidyl and Porphyria, Acute Intermittent

trihexyphenidyl has been researched along with Porphyria, Acute Intermittent in 1 studies

Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.

Porphyria, Acute Intermittent: An autosomal dominant porphyria that is due to a deficiency of HYDROXYMETHYLBILANE SYNTHASE in the LIVER, the third enzyme in the 8-enzyme biosynthetic pathway of HEME. Clinical features are recurrent and life-threatening neurologic disturbances, ABDOMINAL PAIN, and elevated level of AMINOLEVULINIC ACID and PORPHOBILINOGEN in the urine.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gorchein, A1

Other Studies

1 other study available for trihexyphenidyl and Porphyria, Acute Intermittent

ArticleYear
Treatment of Parkinson's disease in a patient with acute intermittent porphyria.
    British journal of clinical pharmacology, 1995, Volume: 40, Issue:1

    Topics: Aged; Antiparkinson Agents; Benserazide; Chlorpromazine; Dopamine Antagonists; Drug Interactions; Fe

1995